The effect of hydroxyquinoline-based gel on pessary-associated bacterial vaginosis: a multicenter randomized controlled trial
American Journal of Obstetrics and Gynecology, ISSN: 0002-9378, Vol: 213, Issue: 5, Page: 729.e1-729.e9
2015
- 21Citations
- 84Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations21
- Citation Indexes20
- 20
- CrossRef5
- Policy Citations1
- Policy Citation1
- Captures84
- Readers84
- 84
Article Description
Pessaries are important options for women with pelvic floor disorders, but many pessary users experience bacterial vaginosis (BV). The aim of this study was to evaluate the effect of TrimoSan gel (Milex Pessaries, Cooper Surgical, Trumbull, CT) on BV prevalence among pessary users. Women presenting for a pessary fitting completed questionnaires on vaginal symptoms and hormone therapy use and underwent a BV BLUE test and slide collection for BV analysis by Nugent’s criteria. Following pessary fitting, women were randomized to either standard pessary care with the use of TrimoSan placed vaginally twice weekly or to standard pessary care without TrimoSan gel. Women returned 2 weeks and 3 months later for a repeat slide collection for Gram stain, BV BLUE testing, and completion of questionnaires on vaginal symptoms and desire to continue the pessary. There were 184 women randomized after successful fitting (92 to the TrimoSan group), and 147 (79%) presented for 3-month follow up. Mean age was 56 ± 16 years; patients were mostly white (57%) or Hispanic (23%), and 36% were using hormone therapy. The groups did not differ in the prevalence of BV by Nugent’s criteria at 2 weeks (20% TrimoSan vs 26% no gel, P =.46) or 3 months (24% TrimoSan vs 23% no gel, P =.82), nor did they differ in BV by BV BLUE testing at 2 weeks (0% TrimoSan vs 4% no gel, P =.12) or 3 months (3% TrimoSan vs 0% no gel, P =.15). The prevalence of at least one vaginal symptom did not differ between groups at 2 weeks (44% TrimoSan vs 45% no gel, P =.98) or 3 months (42% TrimoSan vs 32% no gel, P =.30). The TrimoSan group was equally likely to want to continue their pessary use compared with the standard care group at 2 weeks (90% vs 86%, P =.64) and 3 months (63% vs 60%, P =.76). TrimoSan gel in the first 3 months of pessary use does not decrease the prevalence of BV or vaginal symptoms and does not alter the likelihood of a woman desiring to continue pessary use.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0002937815003968; http://dx.doi.org/10.1016/j.ajog.2015.04.032; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84946490759&origin=inward; https://clinicaltrials.gov/ct2/show/NCT01471457; http://www.ncbi.nlm.nih.gov/pubmed/25935783; https://linkinghub.elsevier.com/retrieve/pii/S0002937815003968; http://www.ajog.org/article/S0002-9378(15)00396-8/abstract; http://linkinghub.elsevier.com/retrieve/pii/S0002937815003968; http://www.ajog.org/retrieve/pii/S0002937815003968; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.ajog.org%2Fretrieve%2Fpii%2FS0002937815003968&rc=0&code=ymob-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.ajog.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa7TxLouCm4g-X_kmKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D960759705%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.ajog.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa7TxLouCm4g-X_kmKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D960759705%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.ajog.org%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa7TxLouCm4g-X_kmKxv%26MAID%3Dndcm7yCQfdCuoIcAtieLwQ%253D%253D%26SERVER%3DWZ6myaEXBLGvmNGtLlDx7g%253D%253D%26ORIGIN%3D960759705%26RD%3DRD&acw=&utt=; http://www.ajog.org/article/S0002937815003968/abstract; http://www.ajog.org/article/S0002937815003968/fulltext; http://www.ajog.org/article/S0002937815003968/pdf
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know